PI3Kα inhibitors inhibit proliferation in ESCC cell lines, but resistance inevitably ensues through multiple mechanisms, including the hyperactivation of mTORC1, the mitogen-activated protein kinase (MAPK) pathway, and c-Myc [180]. This evidence concerns the gene MYC and esophageal squamous cell carcinoma.